%0 Journal Article
%T 免疫治疗在胃癌新辅助治疗中的研究进展
Research Progress of Immunotherapy in Neoadjuvant Therapy of Gastric Cancer
%A 罗永平
%J Journal of Clinical Personalized Medicine
%P 430-435
%@ 2334-3443
%D 2024
%I Hans Publishing
%R 10.12677/jcpm.2024.32063
%X 胃癌(GC)是世界乃至中国最常见的恶性肿瘤之一,其具有异质性高、预后差等特点。手术治疗显著提高了局部晚期胃癌患者的预后。但术后复发率仍然较高,患者长期生存欠佳。临床上无远处转移、临床评估为可手术切除的T2以上或伴有淋巴结转移的患者,首选新辅助化学治疗或新辅助放化学治疗,近年来随着免疫治疗的不断深入研究及其在临床中的广泛应用,越来越多的患者在免疫治疗作为新辅助治疗的治疗方案中获益,从而将免疫治疗纳入指南。基于免疫治疗在新辅助环境中的广泛应用,胃癌的新辅助免疫治疗方案也不断得以调整和完善。随着免疫治疗药物和技术的不断创新与精进,胃癌治疗也逐渐向精准化方向发展,在挫折中不断成长。本文综述了近年来免疫治疗在胃癌新辅助治疗中的研究进展。
Gastric cancer (GC) is one of the most common malignant tumors in the world and even in China, which is characterized by high heterogeneity and poor prognosis. Surgical treatment significantly improves the prognosis of patients with locally advanced gastric cancer. However, the postoperative recurrence rate is still high, and the long-term survival of patients is poor. Neoadjuvant chemotherapy or neoadjuvant radiotherapy is the first choice for patients with no distant metastasis clinically and clinically assessed as T2 or above that can be resectable or accompanied by lymph node metastasis. In recent years, with the continuous in-depth study of immunotherapy and its wide application in clinical practice, more and more patients benefit from immunotherapy as a treatment plan of neoadjuvant therapy, so immunotherapy is included Guidelines. Based on the widespread use of immunotherapy in neoadjuvant settings, neoadjuvant immunotherapy regimens for gastric cancer are constantly being adjusted and refined. With the continuous innovation and improvement of immunotherapy drugs and technologies, the treatment of gastric cancer has gradually developed in the direction of precision, and has continued to grow in setbacks. This article reviews the progress of immunotherapy in neoadjuvant therapy for gastric cancer in recent years.
%K 胃癌,免疫治疗,新辅助治疗
Gastric Cancer
%K Immunotherapy
%K Neoadjuvant Therapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=89433